Ardelyx, Inc. (ARDX)
Largest Insider Buys in Sector
ARDX Stock Price History Chart
ARDX Stock Performance
About Ardelyx, Inc.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing …
Insider Activity of Ardelyx, Inc.
Over the last 12 months, insiders at Ardelyx, Inc. have bought $996,598 and sold $13.37M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $1.34M and sold $5.37M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $10.96M.
The last purchase of 215,868 shares for transaction amount of $996,598 was made by MOTT DAVID M (director) on 2024‑11‑13.
List of Insider Buy and Sell Transactions, Ardelyx, Inc.
| 2024-12-10 | Sale | President & CEO | 25,000 0.0105% | $5.26 | $131,620 | -0.76% | ||
| 2024-11-25 | Sale | President & CEO | 25,000 0.0107% | $5.38 | $134,483 | +2.29% | ||
| 2024-11-20 | Sale | President & CEO | 31,980 0.0132% | $4.79 | $153,328 | +8.13% | ||
| 2024-11-20 | Sale | See Remarks | 4,941 0.002% | $4.79 | $23,690 | +8.13% | ||
| 2024-11-20 | Sale | Chief Medical Officer | 7,366 0.003% | $4.79 | $35,316 | +8.13% | ||
| 2024-11-20 | Sale | Chief Financial Officer | 5,260 0.0022% | $4.79 | $25,219 | +8.13% | ||
| 2024-11-20 | Sale | See Remarks | 7,046 0.0029% | $4.79 | $33,782 | +8.13% | ||
| 2024-11-20 | Sale | Chief Development Officer | 7,184 0.003% | $4.79 | $34,444 | +8.13% | ||
| 2024-11-13 | director | 215,868 0.0924% | $4.62 | $996,598 | +18.00% | |||
| 2024-11-11 | Sale | President & CEO | 2,743 0.0012% | $4.90 | $13,441 | +7.77% | ||
| 2024-11-06 | Sale | Chief Development Officer | 27,171 0.0109% | $6.10 | $165,743 | -18.80% | ||
| 2024-11-04 | Sale | Chief Development Officer | 27,172 0.0115% | $5.95 | $161,673 | -10.53% | ||
| 2024-10-28 | Sale | President & CEO | 25,000 0.0109% | $5.91 | $147,740 | -1.00% | ||
| 2024-10-11 | Sale | President & CEO | 7,500 0.003% | $6.01 | $45,075 | -8.94% | ||
| 2024-09-27 | Sale | Chief Development Officer | 49,564 0.0229% | $6.92 | $342,983 | -14.21% | ||
| 2024-09-26 | Sale | President & CEO | 3,000 0.0013% | $6.07 | $18,210 | +4.78% | ||
| 2024-09-13 | Sale | Chief Development Officer | 5,312 0.0022% | $6.26 | $33,254 | -7.29% | ||
| 2024-09-11 | Sale | President & CEO | 35,000 0.0147% | $5.61 | $196,399 | 0.00% | ||
| 2024-08-27 | Sale | President & CEO | 7,500 0.0032% | $6.22 | $46,635 | -6.03% | ||
| 2024-08-20 | Sale | President & CEO | 32,225 0.0131% | $5.86 | $188,848 | -4.08% |
Insider Historical Profitability
| MOTT DAVID M | director | 1425465 0.6018% | $4.82 | 9 | 0 | +20.54% |
| RAAB MICHAEL | President & CEO | 1150385 0.4857% | $4.82 | 1 | 52 | +247.57% |
| Williams Laura A | Chief Medical Officer | 308745 0.1304% | $4.82 | 1 | 14 | +247.57% |
| Renz Justin A | Chief Financial Officer | 291139 0.1229% | $4.82 | 1 | 19 | +247.57% |
| GRAMMER ELIZABETH A | See Remarks | 185334 0.0782% | $4.82 | 2 | 40 | +116.79% |
Institutional Investor Ownership
| Janus Henderson | $160.86M | 9.42 | 22.05M | -10.59% | -$19.05M | 0.08 | |
| BlackRock | $124.8M | 7.31 | 17.1M | +1.91% | +$2.34M | <0.01 | |
| State Street | $102.85M | 6.02 | 14.09M | -17.62% | -$22M | <0.01 | |
| The Vanguard Group | $97.76M | 5.72 | 13.39M | +2.81% | +$2.67M | <0.01 | |
| Eventide Asset Management | $49.73M | 2.91 | 6.81M | +0.11% | +$54,560.20 | 0.8 |